摘要
目的:系统评价补硒干预对桥本甲状腺炎患者血清抗甲状腺过氧化物酶抗体(anti-thyroid peroxidase antibody,TPOAb)滴度的影响。方法 :经网检索Cochrane图书馆、MEDLINE、EMBASE、CNKI和CBM数据库,同时手工检索相关杂志、会议和学位论文,收集补硒干预治疗桥本甲状腺炎患者的国内外临床随机、对照试验文献。由两名研究者独立选择文献并评价其质量、提取相关数据,且作交叉核对。使用Rev Man 5.0软件进行meta分析。结果 :共入选33篇文献,合计包括3 172例血清TPOAb阳性的桥本甲状腺炎患者,其中补硒干预组1 602例、对照组1 570例。分析结果显示,补硒干预组患者的血清TPOAb滴度显著低于对照组(标准化均数差=-110.38,95%CI:-113.88,-106.88;P<0.01),下降率显著高于对照组[比值比(odds ratio,OR)=2.04,95%CI:1.68,2.48;P<0.01],而升高率显著低于对照组(OR=0.31,95%CI:0.21,0.45;P<0.01)。结论 :补硒干预可在一定程度上降低桥本甲状腺炎患者的血清TPOAb滴度、阻止血清TPOAb滴度升高。
Objective：To evaluate the effect of selenium on anti-thyroid peroxidase antibody（TPOAb） in patients with Hashimoto＇s thyroiditis.Methods：The relative data in Cochrane Library,MEDLINE,EMBASE,CNKI and CBM were searched for on internet and meanwhile the relevant papers of clinically randomized and controlled trials on the selenium intervention for the treatment of Hashimoto＇s thyroiditis were manually retrieved from journals,conference collections and dissertations.The references were independently selected by two researchers and their quality was assessed and the data were extracted and crossly checked.Meta-analysis was performed using Rev Man 5.0 software.Results：There were 3 172 cases of TPOAb positive patients with Hashimoto＇s thyroiditis in a total of 33 studies selected,in which 1 602 cases belonged to a selenium group and 1 570 cases a control group.The analyzed results showed that serum TPOAb titers were lower in the selenium group than in the control group after selenium intervention（standardized mean difference=-110.38,95% CI：-113.88,-106.88; P〈0.01） and the decline rate of TPOAb titers was significantly higher [odds ratio（OR）=2.04,95% CI：1.68,2.48; P〈0.01] while the increase rate was lower in the selenium group than tin the control group（OR=0.31,95% CI：0.21,0.45; P〈0.01）.Conclusion：The intervention by selenium supplementation can decrease the level of serum TPOAb titer in patients with Hashimoto＇s thyroiditis and prevent it from increasing.
作者
李红
李雨辰
何冰
LI Hong LI Yuchen HE Bing(Department of Endocrine, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China Pharmacology Laboratory, School of Pharmacy, Fudan University, Shanghai 200030, China Pharmacological Evaluation Center, Chinese Pharmaceutical Industry Research Institute, Shanghai 201210, China)
出处
《上海医药》
CAS
2017年第21期12-15,共4页
Shanghai Medical & Pharmaceutical Journal
基金
"国家重大新药创制"科技重大专项项目(项目编号:2009ZX0901-007)
关键词
硒
桥本甲状腺炎
抗甲状腺过氧化物酶抗体
selenium
Hashimoto＇s thyroiditis
anti-thyroid peroxidase antibody
